Overview

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.
Phase:
Phase 4
Details
Lead Sponsor:
Third Military Medical University
Treatments:
Candesartan
Candesartan cilexetil